Previous 10 | Next 10 |
Major drug companies, including leading COVID-19 vaccine developers, have joined efforts to discover a potential treatment for long COVID, a condition affecting over 100 million people globally. According to the World Health Organization (WHO), more than 100 million people suffer from long CO...
OCALA, Fla., March 24, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral...
OCALA, Fla., March 23, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral...
AIM ImmunoTech (NYSE:AIM) said the U.S. Food and Drug Administration lifted its clinical hold on an investigational new drug (IND) application allowing the company to begin a phase 2 study of Ampligen for locally advanced pancreatic cancer (AMP-270). The AMP-270 trial, which is expected to be...
Data seen to date indicates that Ampligen® (rintatolimod) could be a potential effective maintenance therapy after systemic chemotherapy in patients with advanced pancreatic cancer In a single-center named patient program, treatment with Ampligen following FOLFIRINOX was as...
OCALA, Fla., March 09, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral...
OCALA, Fla., March 09, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral...
AIM ImmunoTech (NYSE:AIM) said Ampligen following FOLFIRINOX, a chemotherapy combination, showed improved survival rates in patients with pancreatic cancer compared to matched controls of patients who did not receive Ampligen. Ampligen (rintatolimod) was evaluated as a monother...
Ampligen ® (rintatolimod) is being evaluated as a monotherapy to treat pancreatic cancer patients in an Early Access Program (EAP) approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center Treatment with Ampligen following FOLFIRINOX was asso...
AIM ImmunoTech (NYSE:AIM) announces strategic sale of its facility located in New Brunswick, New Jersey for a purchase price of $3.9M. The Company will retain access to space in the New Brunswick facility for activities related to Alferon-N and also intends to lease additi...
News, Short Squeeze, Breakout and More Instantly...
OCALA, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of new pre-clinical data concerning the company’s drug Ampligen as part of a combinational therapy in the...
OCALA, Fla., June 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Pitch Con...
OCALA, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Lunch Break Series ...